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Abstract
Background and Aims: Inflammatory bowel disease [IBD] is characterized by recurrent disease 
flares. The impact of psychosocial wellbeing on the occurrence of flares is unclear. In this 
prospective study, we aimed to evaluate the association between patient-reported psychosocial 
wellbeing and disease flares using continuous monitoring.
Methods: Consecutive IBD patients were recruited from the myIBDcoach telemedicine study cohort. 
Over 12 months, participants reported on disease activity together with anxiety, depression, fatigue, 
perceived stress and life events every 1–3 months. Flares were defined using a combination of clinical 
disease activity and additional measurements. Generalized estimating equation models were used to 
assess associations between psychosocial wellbeing and flares over time. The influences of both the 
presence of psychosocial symptoms in general as well as novel psychosocial symptoms were analysed.
Results: In total, 417 patients were included. Forty-nine patients [11.8%] experienced a flare during 
the study period. The occurrence of life events in the preceding 3 months was positively associated 
with flares (odds ratio [OR] = 1.81; 95% confidence interval [CI] = 1.04–3.17), while the presence of 
anxiety, depression, fatigue and perceived stress in general was not. However, novel perceived 
stress [OR = 2.92; 95% CI = 1.44–5.90] was associated with flares.
Conclusions: The occurrence of life events and novel perceived stress are associated with 
disease flares in the next 3 months, while the presence of perceived stress in general is not. These 
findings underline the importance of continuous personalized monitoring of IBD patients and may 
contribute to the prevention of disease flares.
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1. Introduction
Inflammatory bowel disease [IBD], comprising Crohn’s disease [CD] 
and ulcerative colitis [UC], is a chronic and disabling disease charac-
terized by recurrent periods of disease activity. These flares warrant 
escalation of medical treatment and often require hospitalizations or 
surgery. Recurrent flares may also lead to irreversible bowel damage 
and disease progression [e.g. the occurrence of complications such as 
fistulas and stenosis].1,2 Although biochemical markers are available 
for early detection of disease activity,3 identification of the factors 
contributing to the emergence of flares might be an even more inter-
esting approach to improve the outcome of IBD.
Regarding potentially flare-inducing factors, psychosocial well-
being of patients is of interest. While not systematically monitored 
by healthcare professionals in routine care, a high prevalence of psy-
chological disorders such as anxiety and depression is reported in the 
IBD population.4,5 This may be a consequence of the chronic disease 
itself, but it is also hypothesized that impaired psychosocial well-
being can negatively impact gut health through multiple immune–
neuroendocrine brain–gut interaction pathways.6,7
A large number of studies have investigated the association 
between psychosocial wellbeing and disease activity in IBD, although 
many are limited by their cross-sectional design, thereby potentially 
neglecting the aforementioned bi-directionality of the brain–gut 
axis. When taking into account only longitudinal studies, contradict-
ory results have been reported regarding the effects of anxiety and 
depression on flares.8 Perceived stress and life events have been stud-
ied more extensively and it has been reported that a positive associ-
ation exists between flares and perceived stress in most longitudinal 
studies.9–14 In many studies, however, careful interpretation is advo-
cated due to low sample size and the sole use of clinical disease activ-
ity indices to define flares, because these indices are poor predictors 
of mucosal inflammation.15 Also, perceived stress may affect intes-
tinal motility and may magnify visceral sensitivity, leading to wors-
ening of abdominal symptoms in the absence of inflammation.16,17 
It remains debatable to what extent mood disorders and perceived 
stress are associated with disease flares. For instance, because both 
depression and perceived stress can be present for longer periods,13,18 
it may be relevant to focus on within-subject changes in psychosocial 
wellbeing rather than to analyse only the presence of impaired psy-
chosocial wellbeing preceding flares, which has, to our knowledge, 
not been done before.
Recently, de Jong et al. showed that continuous monitoring at 
home with the telemedicine tool ‘myIBDcoach’ is safe and even 
reduced outpatient visits and hospital admissions.19 myIBDcoach 
continuously monitors patient-reported disease activity and psy-
chosocial wellbeing through questionnaires. This method of data 
collection may provide important insights into psychosocial wellbe-
ing over time. In this prospective study, we aimed to evaluate which 
domains of psychosocial wellbeing, when impaired, were associated 
with future disease flares based on data from the myIBDcoach trial.
2. Materials and methods
2.1. Design and procedures
All data used in this study were derived from the myIBDcoach study 
cohort. The design of this randomized controlled telemedicine study 
has previously been described in detail.19 In short, IBD patients were 
included in four hospitals in the Netherlands [i.e. two academic hos-
pitals, Maastricht University Medical Centre and Leiden University 
Medical Centre, and two regional hospitals, Zuyderland Medical 
Centre Sittard and St. Antonius Hospital Nieuwegein]. Patients 
between 18 and 75 years of age who had a histopathologically cor-
roborated diagnosis of IBD were eligible for inclusion. Exclusion 
criteria comprised insufficient knowledge of the Dutch language, 
lack of internet access by computer, tablet or smartphone, or a hos-
pital admission within 2  weeks prior to inclusion. Also, patients 
with an ileoanal pouch or ileorectal anastomosis were excluded. 
After inclusion, patients were randomized in a 1:1 ratio to standard 
care [control group] or to care through myIBDcoach [intervention 
group] and followed for at least 12 months. Details of the myIB-
Dcoach telemedicine system have been described elsewhere.20 In 
brief, myIBDcoach is a secure webpage which is accessible through 
computer, tablet or smartphone. The system provides monthly moni-
toring modules, including questions regarding disease activity, use 
of medication, treatment adherence, smoking status and psycho-
social wellbeing. When patients achieved sustained remission [i.e. 
low clinical activity for three consecutive months], the system was 
allowed to complete the monitoring module once every 3 months. 
When predefined thresholds, for instance on clinical disease activity, 
were exceeded, a healthcare provider of the local team contacted 
the patient for further assessment. The study was approved by the 
Medical Research Ethics Committee of the Maastricht University 
Medical Centre, being applicable to all participating centres. This 
trial was registered at ClinicalTrials.gov [NCT02173002].
For the present study, we included all patients who received care 
through myIBDcoach [i.e. the intervention arm of the randomized 
study]. Patients without a single period of documented remission 
during follow-up were excluded because this period of remission was 
required to analyse the association between the development of dis-
ease flares and preceding psychosocial wellbeing. Detailed baseline 
data at the time of inclusion in myIBDcoach [i.e. patient character-
istics, disease phenotype, disease duration and previous treatments] 
were collected by scrutinizing patient files using standardized regis-
tration forms. During the 12 months of follow-up, questionnaires 
on disease activity [MIAH-questionnaire21] and psychosocial wellbe-
ing [i.e. anxiety, depression, fatigue, perceived stress and life-events] 
were completed every 1–3 months.
2.2. Definitions
In line with previous analyses based on the myIBDcoach tool, flares 
were defined as clinical symptoms [i.e. positive score on the MIAH-
questionnaire or symptoms during outpatient visits] indicative of 
disease activity in combination with at least one of the following: 
concurrent calprotectin >250  µg/g in the stool or active disease 
determined by endoscopy, magnetic resonance imaging or computed 
tomography. In daily practice, in case of clinically severe symptoms 
suggestive for IBD disease activity, the treating physician occasion-
ally judged these symptoms to be evident enough to adjust therapy. 
Therefore, to capture all flares, also clinical episodes were defined 
as flares if symptoms suggestive of IBD disease activity resulted in a 
dose escalation or initiation of a new drug to induce remission.
Psychosocial parameters were assessed through a patient-reported 
questionnaire containing one question for each psychosocial domain 
of interest [Table 1]. For anxiety, depression and fatigue, questions 
could be answered on a five-point Likert-scale [i.e. ‘seldom or never’, 
‘occasionally’, ‘regularly’, ‘often’, or ‘always or almost always’]. Cut-
offs were determined based on the smallest Euclidian distances com-
pared to validated questionnaires [i.e. HADS-A,22 HADS-D22 and 
VVS23]. The performance of the questionnaire is shown in Table 1. 
For perceived stress, we used a visual analogue scale on which a 
patient could report on their current stress level [range from 1 to 10] 
in which a higher score reflects higher stress levels. This scale showed 
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a moderate but significant correlation with the Cohen’s Perceived 
Stress Scale [PSS; r = 0.654].24 However, note that the PSS is based on 
perceived stress during the previous month, while our scale measures 
current stress levels. A cut-off point of 4, based on expert opinion of 
our team of gastroenterologists and our population’s average, was 
used to differentiate low vs high perceived stress levels. The occur-
rence of life events was scored in a binary approach [i.e. yes/no]. The 
underlying reason for the life event was answered as an open-ended 
question and was therefore neglected in the analysis.
2.3. Statistical analysis
Baseline characteristics are presented as means with correspond-
ing standard deviations [SD] for numerical variables with a normal 
distribution, as medians with corresponding interquartile ranges 
[IQR] for numerical variables without a normal distribution, and 
as number of patients [%] for categorical variables. For comparison 
between groups, the independent-samples t-test and chi-square test 
or Fisher’s exact test, when appropriate, were used for numerical and 
categorical variables, respectively.
Generalized estimating equation [GEE] models were used to 
identify associations between psychosocial wellbeing and the sub-
sequent development of flares over time. This method is used to 
account for repeated measures within the same patient, where the 
covariance pattern was unstructured. Because it was unknown how 
long a patient was in remission when entering the study, the first 
3 months of all patients were ignored in the analyses. Next, each 
month of follow-up was considered either as positive or negative 
with respect to flares, according to the aforementioned definition. 
Also, patient-reported psychosocial wellbeing was assessed with 
intervals of 1 month using the aforementioned cut-offs. When active 
disease was present at baseline or when a flare occurred during 
follow-up, the subsequent 6 months were excluded from the ana-
lysis to correct for a potential effect of disease activity and the sub-
sequent remission-induction therapy on the psychosocial wellbeing 
of a patient. This can be considered as a wash-out period for both 
gastrointestinal inflammation and psychosocial imbalance caused 
by the preceding flare. Because patients could choose to fill in the 
questionnaires either once every month or once every 3 months, all 
models estimate the effect of psychosocial wellbeing on disease activ-
ity in the next quarter.
In the first GEE model, the association between flares and 
the presence of psychosocial symptoms in general was assessed. 
Predefined cut-offs were used to indicate the presence or absence 
of all psychosocial factors available in myIBDcoach, regardless 
of the prior psychosocial wellbeing of the patient. In the second 
GEE model, the association between flares and novel psychosocial 
symptoms was assessed. Here, differences in psychosocial param-
eters over time were determined to separate novel symptoms from 
pre-existing symptoms. At each time point the alteration in psy-
chosocial parameters was regarded as positive when this change 
exceeded the cut-off values of these parameters (e.g. from ‘seldom 
or never feeling depressed’ [i.e. score 1] to ‘often feeling depressed’ 
[i.e. score 4]) in the 3 months preceding this time point. Life events 
were only analysed in the first model, because life events are ‘novel’ 
by definition and therefore the second model is not applicable. To 
ensure a prospective association between the psychosocial param-
eters and subsequent flares, psychosocial parameters were not taken 
into account as predictors when positive at the same time point as 
the flare. For example, when a patient experienced a flare between 
time points 5 and 6, the latter was regarded as the ‘time point of 
flare’ and psychosocial scores from time points 3 to 5 were used in 
the model as explanatory variables.
All results were analysed using a multivariable model including 
gender, disease phenotype, disease duration at baseline and smoking 
status at baseline to correct for their potential confounding effect on 
disease flares. Although our study was underpowered for additional 
confounders, medication use at baseline was added to the model as a 
sensitivity analysis. All analyses were conducted using a significance 
level of 0.05. Two-sided p-values ≤ 0.05 were considered as statis-
tically significant.
3. Results
In total, 465 patients were allocated to the myIBDcoach interven-
tion.19 Of these, nine never started using the application and 18 were 
lost to follow-up. After exclusion of these patients and those with 
IBD unclassified [IBD-U, n = 3], those without any completed ques-
tionnaire [n  = 11] and those without a single period of remission 
[n = 7], 417 patients were eligible for this study. Of these, 49 [11.8%] 
developed a flare during follow-up [i.e. change from inactive to 
active disease]. Two of these patients developed a second flare after 
remission was re-obtained. Flares were defined by clinical symptoms 
in combination with an elevated faecal calprotectin, active disease on 
endoscopy or imaging, and adjustment of therapy by a gastroenter-
ologist in 14 [27.4%], 21 [41.2%] and 16 [31.4%] cases, respectively. 
Baseline characteristics of these patients [i.e. relapsers] compared to 
those not developing a flare during follow-up [i.e. non-relapsers] are 
presented in Table 2. No significant differences in baseline character-
istics were found between relapsers and non-relapsers, except for a 
greater proportion of smokers in the latter group [p = 0.005]. The 
average time from inclusion to their first disease flare for relapsers 
was 6.4 [SD = 2.6] months.
Table 1. Overview of psychosocial questionnaire used in the myIBDcoach telemedicine tool
Domain Question Scale Cut-off Performance vs validated  
questionnaire [sens/spec]
Anxiety In the past two weeks I … felt anxious. Likert [1–5] 2 [occasionally] HADS-A22 [64/82]
Depression In the past two weeks I … felt miserable or depressed. Likert [1–5] 3 [frequently] HADS-D22 [73/93]
Fatigue In the past two weeks I … felt tired. Likert [1–5] 3 [frequently] VVV23 [90/100]
Perceived stress Rate your current stress level on a scale from 1 to 10, what 
number would you give?
VAS [1–10] NA PSS24 [R = 0.654]
Life events Did you recently experience any important or drastic events 
which influenced your feelings?
Dichotomous NA NA
VAS, visual analogue scale; NA, not applicable; sens, sensitivity; spec, specificity; HADS-D, Hospital Anxiety and Depression Scale – Depression; HADS-A, 
Hospital Anxiety and Depression Scale – Anxiety; VVV, Verkorte VermoeidheidVragenlijst [translated: Short Fatigue Questionnaire]; PSS, Perceived Stress Scale.
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Regarding the presence of psychosocial symptoms in general, 
only the occurrence of life events (odds ratio [OR]  =  1.81, 95% 
confidence interval [95% CI]  =  1.04–3.17) was associated with 
flare development in the next 3 months [Table 3]. Neither anxiety 
[OR  =  0.73, 95% CI  =  0.38–1.39], depression [OR  =  1.33, 95% 
CI = 0.70–2.55], fatigue [OR = 1.91, 95% CI = 0.98–3.73] nor per-
ceived stress [OR  =  1.09, 95% CI  =  0.62–1.91] were statistically 
significantly associated with flare development. Regarding novel 
psychosocial symptoms [i.e. alteration exceeding cut-off], only per-
ceived stress [OR = 2.92, 95% CI = 1.44–5.90] was associated with 
subsequent flares [Table  3], independent of the presence of other 
psychosocial factors in general. No statistically significant associa-
tion with subsequent flares was found in this second GEE model for 
anxiety [OR = 1.12, 95% CI = 0.50–2.51], depression [OR = 1.28, 
95% CI = 0.54–3.07] and fatigue [OR = 1.58, 95% CI = 0.79–3.15]. 
All results were adjusted for gender, disease phenotype, disease dura-
tion and smoking status. When results were analysed for CD and 
UC separately, the association between flares and both life events 
and perceived stress tended to be stronger in CD. However, due to 
the small number of relapses, the study was not powered to analyse 
these associations and the results should be interpreted with care.
In a first sensitivity analysis, medication use at baseline was 
added to the model. By applying this, all results remained similar. 
As a second sensitivity analysis, different cut-offs of the questions 
regarding depression, anxiety, fatigue and perceived stress were used. 
For depression, anxiety and fatigue, neither higher nor lower cut-
offs changed the results. For novel perceived stress, a difference was 
observed. Where cut-offs higher than 4 were chosen, perceived stress 
was no longer statistically significant [cut-off 5: OR = 1.52, 95% 






Crohn’s disease, n [%] 26 [53.1] 222 [60.3] 0.331
Male, n [%] 15 [30.6] 158 [42.9] 0.100
Montreal at diagnosisa
 Age [CD and UC] 0.600
  A1, n [%] 8 [16.3] 60 [16.3]
  A2, n [%] 26 [53.1] 219 [59.5]
  A3, n [%] 15 [30.6] 89 [24.2]
 Disease location [CD] 0.741
  L1, n [%] 7 [26.9] 73 [32.9]
  L2, n [%] 6 [23.1] 55 [24.8]
  L3, n [%] 13 [50.0] 94 [42.3]
 Disease behaviour [CD] 0.958
  B1 [CD], n [%] 16 [61.6] 134 [60.6]
  B2 [CD], n [%] 7 [26.9] 57 [25.8]
  B3 [CD], n [%] 3 [11.5] 30 [13.6]
 Disease extent [UC] 0.768
  E1 [UC], n [%] 2 [8.7] 19 [12.8]
  E2 [UC], n [%] 10 [43.5] 69 [46.3]
  E3 [UC], n [%] 11 [47.8] 61 [40.9]
Age at baseline [years], mean [SD] 46.08 [15.24] 43.95 [13.71] 0.313
Disease duration at baseline [years], median [IQR] 4.65 [3.38–17.8] 10.8 [5.2–20.8] 0.172
Active disease at baseline, n [%] 4 [8.2] 28 [7.6] 0.908
Medication use at baseline 0.434
 No medication/5-ASA, n [%] 15 [30.6] 142 [39.3]
 Immunomodulators, n [%] 16 [32.7] 93 [25.8]
 Biologics, n [%] 18 [36.7] 126 [34.9]
Current smoking at baseline, n [%] 1 [2.0] 65 [17.7] 0.005*
History of IBD-related surgery at baseline, n [%] 5 [10.2] 41 [11.1] 0.470
n, number of patients; CD, Crohn’s disease; UC, ulcerative colitis; SD, standard deviation; IQR, interquartile range; 5-ASA, 5-aminosalicylic acid. Age was 
defined as below 17 years [A1], between 17 and 40 years [A2] and above 40 years [A3]. Disease location of CD was defined as ileal involvement [L1], exclusive 
colonic involvement [L2] and ileocolonic involvement [L3]. Disease behaviour of CD was defined as non-stricturing/non-penetrating [B1], stricturing [B2], pen-
etrating [B3]. Disease extent of UC was defined as ulcerative proctitis [E1], left-sided UC [E2] and extensive UC [E3].
*p < 0.05.
aAccording to Montreal Classification.36
Table  3. Association between both the presence of psychosocial 
symptoms in general [GEE model 1] as well as novel psychosocial 
symptoms [GEE model 2] and disease flares
GEE model 1: pres-
ence of psychosocial 
symptoms in general
GEE model 2: 
novel psychosocial 
symptoms
OR 95% CI OR 95% CI
Anxiety 0.73 0.38–1.39 1.12 0.50–2.51
Depression 1.33 0.70–2.55 1.28 0.54–3.07
Fatigue 1.91 0.98–3.73 1.58 0.79–3.15
Perceived stress 1.09 0.62–1.91 2.92 1.44–5.90**
Life events 1.81 1.04–3.17* NA NA
OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable. All 
analyses were adjusted for gender, disease phenotype, disease duration at base-
line, and smoking status at baseline.
*p < 0.05; **p < 0.01.
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CI = 0.67–3.45], while cut-offs below 4 remained statistically signifi-
cant [cut-off 3: OR = 2.24, 95% CI = 1.02–4.90].
4. Discussion
In this prospective continuous telemedicine monitoring study, we 
evaluated the effect of psychosocial wellbeing on subsequent disease 
flares. A positive association was found between both life events as 
well as perceived stress and disease flares. We thus identified a rele-
vant difference between the presence of perceived stress in general, 
irrespective of changes over time, and novel perceived stress. Only 
the latter was prospectively associated with occurrence of disease 
flares in the next 3 months. Anxiety, depression and fatigue were not 
associated with disease flares.
The observed association between disease activity and perceived 
stress has previously been described. However, the power of many 
studies was limited due to methodological flaws such as cross-
sectional analyses, small sample size and the lack of objective meas-
urements of disease activity.25 Because IBD patients often experience 
irritable bowel syndrome-like complaints, the sole use of clinical dis-
ease activity indices to define flares may give an overestimation of 
relapses and therefore additional markers of inflammation are needed. 
So far, only a limited number of longitudinal studies have used a com-
bination of symptoms and additional measurements [e.g. calprotectin 
or endoscopy] to define flares.11,13,14,26 In a longitudinal study using a 
combination of clinical disease activity index and faecal calprotectin 
concentration, short-term perceived stress was positively associated 
with subsequent IBD symptoms, but not with ‘objectively’ assessed 
inflammation by faecal calprotectin measurement.13 These findings 
may explain some contradictory results from earlier studies and sup-
port our findings concerning the absence of an association between 
the presence of perceived stress in general and flares. Nonetheless, 
a difference between the presence of perceived stress in general and 
novel perceived stress was observed here. In many studies, ‘short-
term’ perceived stress has been analysed by using a questionnaire 
comprising the past month [e.g. Cohen Perceived Stress Scale24 or 
Perceived Stress Questionnaire27]. Unfortunately, these questionnaires 
are insensitive to perceived stress in the period prior to this month. 
Therefore, exposure time to perceived stress is unknown and both 
‘novel’ and ‘longer lasting’ stress are measured. To analyse the effect 
of intra-individual changes of perceived stress over time, longitudinal 
follow-up of both the outcome variable [i.e. disease flares] and per-
ceived stress is necessary. To our knowledge, in only a few studies 
have both variables been repeatedly measured during follow-up.9–13,26 
Of these, none used the repetitive assessments to differentiate novel 
perceived stress from chronic or pre-existing perceived stress.
In the present study, we observed a clear difference between the 
effect of perceived stress in general and the effect of novel perceived 
stress. In healthy individuals, both internal and external stressors 
are in balance with behavioral and physiological adaptive responses. 
Perceived stress may become detrimental when this balance is dis-
turbed [e.g. via acute stressors].28 It is hypothesized that perceived 
stress may affect the brain–gut axis through: [1] activation of the 
hypothalamic–pituitary–adrenal axis and subsequent release of cor-
ticotropin-releasing factor and cortisol, which have direct and indir-
ect gastrointestinal immunostimulatory effects; [2] decreased activity 
of the vagal nerve and thereby a decreased anti-inflammatory effect; 
[3] increased activation of the sympathetic nervous system and sub-
sequent increase of inflammatory cytokines, activation of the NF-kB 
pathway, and activation of mast cells; and [4] peripheral release of 
substance P by the enteric nervous system, acting as an inflammatory 
cytokine and stimulator of mast cells.6,16 It is hypothesized that after 
such disturbance, homeostasis usually returns in most individuals.28 
Therefore, we suggest that during prolonged stress, individuals can 
adapt to this new situation. This might explain why, in our study, only 
novel perceived stress was associated with flares. However, another 
longitudinal study observed long-term perceived stress [i.e. covering 
2 years prior to measurement] to be associated with flares in the fol-
lowing 8 months, while short-term perceived stress [i.e. covering the 
month prior to measurement] was not.26 However, their explanation 
of a proposed lengthy time scale for the evolution of effects of stress 
on the intestines was primarily based on animal studies. Coping 
strategies and consequent adaptation to chronic stress may be dif-
ferent in humans. It is hypothesized that chronic stress enhances the 
effects of acute stress through greater and more prolonged increases 
in sympathetic activation following a stressor, although supporting 
evidence for this is scarce.16 Future studies regarding perceived stress 
and disease flares, using the same methodology as the present study, 
should be performed to validate our findings.
The occurrence of life events was also associated with the devel-
opment of a flare in the next 3 months. The most frequently identi-
fied type of life events were work-related [19.4%; e.g. dismissal or 
reorganization], personal health issues [10.9%], moving house or 
renovating a house [10.9%], or the death of relatives or good friends 
[9.1%]. The effect of life events on future disease activity is smaller 
when compared to perceived stress. Although life events by definition 
are correlated with perceived stress, the way of coping will determine 
whether the life event as a stressor leads to more perceived stress or 
not. We speculate that only patients with insufficient coping strate-
gies will experience an increase in perceived stress. Unfortunately, our 
study is not designed to analyse these effects. However, this hypoth-
esis is supported by findings of another prospective study in which a 
combination of low stress and a good coping strategy was associated 
with the lowest risk of a disease flare.12 Debate remains as contradict-
ory results on the influence of life events have been reported by oth-
ers, possibly due to differences in study design and methodology.8,29
In this study, no association was found between anxiety, depres-
sion or fatigue and subsequent disease flares. Anxiety and depression 
as comorbidities have extensively been studied in IBD patients and 
in a recent systematic review it has been shown that the prevalence 
rate of anxiety [20%] and depression [15%] is high in IBD com-
pared to prevalence rates in the general population [7.3% and 3.2%, 
respectively].5,30,31 However, a meta-analysis of prospective studies on 
the impact of a depressive state on disease activity showed no statis-
tically significant association, which is in line with our study.32 The 
association between both anxiety and disease flares as well as fatigue 
and disease flares has not very frequently been studied. Anxiety 
seemed not to be associated, as in our study, with disease flares.11,12,33 
Although longitudinal evidence for an association between fatigue 
and flares is lacking, a high prevalence of fatigue in active IBD has 
been observed.34 In our study, this association could not be confirmed.
The strength of this study is the systematic and continuous moni-
toring of both disease activity and psychosocial wellbeing over a 
12-month period in a large study population. Additionally, we were 
able to analyse within-subject changes of psychosocial wellbeing. Also, 
we defined disease flares using a combination of clinical disease activ-
ity [i.e. MIAH-questionnaire] and additional parameters [i.e. faecal 
calprotectin, imaging or outpatient clinic visit with treatment adjust-
ment]. Some limitations also need to be addressed. First and most 
importantly, we did not use validated questionnaires for psychoso-
cial wellbeing in the telemedicine tool. The questionnaires in myIBD-
coach were designed to screen for several relevant aspects potentially 
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associated with patients’ wellbeing and these questionnaires had to be 
concise for repeated use in a daily clinical practice setting. We therefore 
chose to apply only one ‘screening’ question per domain to limit loss of 
adherence. However, previous studies have shown that single-question 
questionnaires can correlate well with comprehensive questionnaires 
[e.g. for perceived stress35]. Second, we were not able to obtain reliable 
data on the use of non-steroidal anti-inflammatory drugs, the use of 
antibiotics or incident infections from the myIBDcoach tool, whereas 
several studies suggest that these variables are associated with disease 
flares.29 On the other hand, a large longitudinal population-based study 
showed no effect of either of these variables and therefore we believe 
that the potential confounding effect, if present, is only minimal.9
Currently, we believe that the merit of psychosocial wellbeing 
in IBD patients is underestimated and hardly routinely assessed in 
daily practice. In this study, we addressed that particular attention 
should be paid to novel perceived stress and life events and our 
data underline a possible need for tight psychosocial monitoring 
of IBD patients. Our findings concerning the association between 
novel perceived stress and disease flares need confirmation by future 
studies and such studies should take coping strategies into account. 
Eventually, personalized interventions in those who are at risk of 
developing flares are worthy of further study.
In conclusion, the occurrence of recent life events and novel per-
ceived stress were prospectively associated with the incidence of IBD 
disease flares in the next 3 months, while the presence of perceived 
stress in general was not. Also, no association was found between 
disease flares and anxiety, depression or fatigue. This study under-
lines the importance of continuous personalized monitoring of IBD 
patients, which may contribute to the prevention of disease flares.
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